Skip to main content

Co-Administration of TiO2 Nanowired Mesenchymal Stem Cells with Cerebrolysin Potentiates Neprilysin Level and Reduces Brain Pathology in Alzheimer’s Disease

Molecular Neurobiology volume 55, pages 300–311 (2018)Cite this article

Abstract

Neprilysin (NPL), the rate-limiting enzyme for amyloid beta peptide (AβP), appears to play a crucial role in the pathogenesis of Alzheimer’s disease (AD). Since mesenchymal stem cells (MSCs) and/or cerebrolysin (CBL, a combination of neurotrophic factors and active peptide fragments) have neuroprotective effects in various CNS disorders, we examined nanowired delivery of MSCs and CBL on NPL content and brain pathology in AD using a rat model. AD-like symptoms were produced by intraventricular (i.c.v.) administration of AβP (1-40) in the left lateral ventricle (250 ng/10 μl, once daily) for 4 weeks. After 30 days, the rats were examined for NPL and AβP concentrations in the brain and related pathology. Co-administration of TiO2-nanowired MSCs (106 cells) with 2.5 ml/kg CBL (i.v.) once daily for 1 week after 2 weeks of AβP infusion significantly increased the NPL in the hippocampus (400 pg/g) from the untreated control group (120 pg/g; control 420 ± 8 pg/g brain) along with a significant decrease in the AβP deposition (45 pg/g from untreated control 75 pg/g; saline control 40 ± 4 pg/g). Interestingly, these changes were much less evident when the MSCs or CBL treatment was given alone. Neuronal damages, gliosis, and myelin vesiculation were also markedly reduced by the combined treatment of TiO2, MSCs, and CBL in AD. These observations are the first to show that co-administration of TiO2-nanowired CBL and MSCs has superior neuroprotective effects in AD probably due to increasing the brain NPL level effectively, not reported earlier.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Hersh LB, Rodgers DW (2008) Neprilysin and amyloid beta peptide degradation. Curr Alzheimer Res 5(2):225–231

    CAS  Article  PubMed  Google Scholar 

  2. Mazur-Kolecka B, Frackowiak J (2006) Neprilysin protects human neuronal progenitor cells against impaired development caused by amyloid-beta peptide. Brain Res 1124(1):10–18

    CAS  Article  PubMed  Google Scholar 

  3. Nilsson P, Loganathan K, Sekiguchi M, Winblad B, Iwata N, Saido TC, Tjernberg LO (2015) Loss of neprilysin alters protein expression in the brain of Alzheimer’s disease model mice. Proteomics 15(19):3349–3355. doi:10.1002/pmic.201400211

    CAS  Article  PubMed  Google Scholar 

  4. Hüttenrauch M, Baches S, Gerth J, Bayer TA, Weggen S, Wirths O (2015) Neprilysin deficiency alters the neuropathological and behavioral phenotype in the 5XFAD mouse model of Alzheimer’s disease. J Alzheimers Dis 44(4):1291–1302. doi:10.3233/JAD-142463

    PubMed  Google Scholar 

  5. Wang DS, Lipton RB, Katz MJ, Davies P, Buschke H, Kuslansky G, Verghese J, Younkin SG et al (2005) Decreased neprilysin immunoreactivity in Alzheimer disease, but not in pathological aging. J Neuropathol Exp Neurol 64(5):378–385

  6. Duyckaerts C, Potier MC, Delatour B (2008) Alzheimer disease models and human neuropathology: similarities and differences. Acta Neuropathol 115(1):5–38

    Article  PubMed  Google Scholar 

  7. El-Amouri SS, Zhu H, Yu J, Marr R, Verma IM, Kindy MS (2008) Neprilysin: an enzyme candidate to slow the progression of Alzheimer’s disease. Am J Pathol 172(5):1342–1354. doi:10.2353/ajpath.2008.070620

  8. Nalivaeva NN, Fisk LR, Belyaev ND, Turner AJ (2008) Amyloid-degrading enzymes as therapeutic targets in Alzheimer’s disease. Curr Alzheimer Res 5(2):212–224

    CAS  Article  PubMed  Google Scholar 

  9. Tayler H, Fraser T, Miners JS, Kehoe PG, Love S (2010) Oxidative balance in Alzheimer’s disease: relationship to APOE, Braak tangle stage, and the concentrations of soluble and insoluble amyloid-β. J Alzheimers Dis 22(4):1363–1373. doi:10.3233/JAD-2010-101368

    CAS  Article  PubMed  Google Scholar 

  10. Nalivaeva NN, Turner AJ (2016) Role of ageing and oxidative stress in regulation of amyloid-degrading enzymes and development of neurodegeneration. Curr Aging Sci 10(1):32–40

    Article  Google Scholar 

  11. Song JH, Yu JT, Tan L (2015) Brain-derived neurotrophic factor in Alzheimer’s disease: risk, mechanisms, and therapy. Mol Neurobiol 52(3):1477–1493. doi:10.1007/s12035-014-8958-4

    CAS  Article  PubMed  Google Scholar 

  12. Zhang L, Fang Y, Lian Y, Chen Y, Wu T, Zheng Y, Zong H, Sun L et al (2015) Brain-derived neurotrophic factor ameliorates learning deficits in a rat model of Alzheimer’s disease induced by aβ1-42. PLoS One 10(4):e0122415. doi:10.1371/journal.pone.0122415

  13. Diniz BS, Teixeira AL (2011) Brain-derived neurotrophic factor and Alzheimer’s disease: physiopathology and beyond. NeuroMolecular Med 13(4):217–222. doi:10.1007/s12017-011-8154-x

    CAS  Article  PubMed  Google Scholar 

  14. Hachisu M, Konishi K, Hosoi M, Tani M, Tomioka H, Inamoto A, Minami S, Izuno T et al (2015) Beyond the hypothesis of serum anticholinergic activity in Alzheimer’s disease: acetylcholine neuronal activity modulates brain-derived neurotrophic factor production and inflammation in the brain. Neurodegener Dis 15(3):182–187. doi:10.1159/000381531

  15. Iijima-Ando K, Hearn SA, Granger L, Shenton C, Gatt A, Chiang HC, Hakker I, Zhong Y et al (2008) Overexpression of neprilysin reduces alzheimer amyloid-beta42 (Abeta42)-induced neuron loss and intraneuronal Abeta42 deposits but causes a reduction in cAMP-responsive element-binding protein-mediated transcription, age-dependent axon pathology, and premature death in Drosophila. J Biol Chem 283(27):19066–19076. doi:10.1074/jbc.M710509200

  16. Carpentier M, Robitaille Y, DesGroseillers L, Boileau G, Marcinkiewicz M (2002) Declining expression of neprilysin in Alzheimer disease vasculature: possible involvement in cerebral amyloid angiopathy. J Neuropathol Exp Neurol 61(10):849–856

    CAS  Article  PubMed  Google Scholar 

  17. Katsuda T, Tsuchiya R, Kosaka N, Yoshioka Y, Takagaki K, Oki K, Takeshita F, Sakai Y et al (2013) Human adipose tissue-derived mesenchymal stem cells secrete functional neprilysin-bound exosomes. Sci Rep 3:1197. doi:10.1038/srep01197

  18. Kim JY, Kim DH, Kim JH, Lee D, Jeon HB, Kwon SJ, Kim SM, Yoo YJ et al (2012) Soluble intracellular adhesion molecule-1 secreted by human umbilical cord blood-derived mesenchymal stem cell reduces amyloid-β plaques. Cell Death Differ 19(4):680–691. doi:10.1038/cdd.2011.140

  19. Yang H, Xie Z, Wei L, Yang H, Yang S, Zhu Z, Wang P, Zhao C et al (2013) Human umbilical cord mesenchymal stem cell-derived neuron-like cells rescue memory deficits and reduce amyloid-beta deposition in an AβPP/PS1 transgenic mouse model. Stem Cell Res Ther 4(4):76. doi:10.1186/scrt227

  20. Habisch HJ, Schmid B, von Arnim CA, Ludolph AC, Brenner R, Storch A (2010) Efficient processing of Alzheimer’s disease amyloid-beta peptides by neuroectodermally converted mesenchymal stem cells. Stem Cells Dev 19(5):629–633. doi:10.1089/scd.2009.0045

    CAS  Article  PubMed  Google Scholar 

  21. Sharma HS, Castellani RJ, Smith MA, Sharma A (2012) The blood-brain barrier in Alzheimer’s disease: novel therapeutic targets and nanodrug delivery. Int Rev Neurobiol 102:47–90. doi:10.1016/B978-0-12-386986-9.00003-X

    CAS  Article  PubMed  Google Scholar 

  22. Sharma HS, Muresanu DF, Sharma A (2016) Alzheimer’s disease: cerebrolysin and nanotechnology as a therapeutic strategy. Neurodegener Dis Manag 6(6):453–456

    Article  PubMed  Google Scholar 

  23. Guide for the Care and Use of Laboratory Animals (2011) 8th edition, National Institute of Health, The National Academies Press, Washington DC, www.nap.edu

  24. Vorobyov V, Kaptsov V, Gordon R, Makarova E, Podolski I, Sengpiel F (2015) Neuroprotective effects of hydrated fullerene C60: cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer’s disease. J Alzheimers Dis 45(1):217–233. doi:10.3233/JAD-142469

    CAS  PubMed  Google Scholar 

  25. Anand A, Banik A, Thakur K, Masters CL (2012) The animal models of dementia and Alzheimer’s disease for pre-clinical testing and clinical translation. Curr Alzheimer Res 9(9):1010–1029

    CAS  Article  PubMed  Google Scholar 

  26. Alzoubi KH, Alhaider IA, Tran TT, Mosely A, Alkadhi KK (2011) Impaired neural transmission and synaptic plasticity in superior cervical ganglia from β-amyloid rat model of Alzheimer’s disease. Curr Alzheimer Res 8(4):377–384

    CAS  Article  PubMed  Google Scholar 

  27. Schmidt SD, Mazzella MJ, Nixon RA, Mathews PM (2012) Aβ measurement by enzyme-linked immunosorbent assay. Methods Mol Biol 849:507–527. doi:10.1007/978-1-61779-551-0_34

    CAS  Article  PubMed  Google Scholar 

  28. Lachno DR, Evert BA, Maloney K, Willis BA, Talbot JA, Vandijck M, Dean RA (2015) Validation and clinical utility of ELISA methods for quantification of amyloid-β of peptides in cerebrospinal fluid specimens from Alzheimer’s disease studies. J Alzheimers Dis 45(2):527–542

    CAS  PubMed  Google Scholar 

  29. Schmidt SD, Nixon RA, Mathews PM (2005) ELISA method for measurement of amyloid-beta levels. Methods Mol Biol 299:279–297

    CAS  PubMed  Google Scholar 

  30. Miners JS, Verbeek MM, Rikkert MO, Kehoe PG, Love S (2008) Immunocapture-based fluorometric assay for the measurement of neprilysin-specific enzyme activity in brain tissue homogenates and cerebrospinal fluid. J Neurosci Methods 167(2):229–236

    CAS  Article  PubMed  Google Scholar 

  31. Krämer HH, He L, Lu B, Birklein F, Sommer C (2009) Increased pain and neurogenic inflammation in mice deficient of neutral endopeptidase. Neurobiol Dis 35(2):177–183. doi:10.1016/j.nbd.2008.11.002

    Article  PubMed  Google Scholar 

  32. Huang H, Bihaqi SW, Cui L, Zawia NH (2011) In vitro Pb exposure disturbs the balance between Aβ production and elimination: the role of AβPP and neprilysin. Neurotoxicology 32(3):300–306. doi:10.1016/j.neuro.2011.02.001

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  33. Sharma HS, Feng L, Lafuente JV, Muresanu DF, Tian ZR, Patnaik R, Sharma A (2015) TiO2-Nanowired delivery of mesenchymal stem cells thwarts diabetes- induced exacerbation of brain pathology in heat stroke: an experimental study in the rat using morphological and biochemical approaches. CNS Neurol Disord Drug Targets 14(3):386–399

    CAS  Article  PubMed  Google Scholar 

  34. Tian ZR, Sharma A, Nozari A, Subramaniam R, Lundstedt T, Sharma HS (2012) Nanowired drug delivery to enhance neuroprotection in spinal cord injury. CNS Neurol Disord Drug Targets 11(1):86–95

    CAS  Article  PubMed  Google Scholar 

  35. Sharma A, Menon P, Muresanu DF, Ozkizilcik A, Tian ZR, Lafuente JV, Sharma HS (2016) Nanowired drug delivery across the blood-brain barrier in central nervous system injury and repair. CNS Neurol Disord Drug Targets 15(9):1092–1117

    CAS  Article  PubMed  Google Scholar 

  36. Menon PK, Muresanu DF, Sharma A, Mössler H, Sharma HS (2012) Cerebrolysin, a mixture of neurotrophic factors induces marked neuroprotection in spinal cord injury following intoxication of engineered nanoparticles from metals. CNS Neurol Disord Drug Targets 11(1):40–49

    CAS  Article  PubMed  Google Scholar 

  37. Sharma HS, Olsson Y, Dey PK (1990) Changes in blood-brain barrier and cerebral blood flow following elevation of circulating serotonin level in anesthetized rats. Brain Res 517(1–2):215–223

    CAS  Article  PubMed  Google Scholar 

  38. Sharma HS, Dey PK (1986) Influence of long-term immobilization stress on regional blood-brain barrier permeability, cerebral blood flow and 5-HT level in conscious normotensive young rats. J Neurol Sci 72(1):61–76

    CAS  Article  PubMed  Google Scholar 

  39. Olsson Y, Sharma HS, Pettersson CA (1990) Effects of p-chlorophenylalanine on microvascular permeability changes in spinal cord trauma. An experimental study in the rat using 131I-sodium and lanthanum tracers. Acta Neuropathol 79(6):595–603

    CAS  Article  PubMed  Google Scholar 

  40. Sharma HS, Cervós-Navarro J (1990) Brain oedema and cellular changes induced by acute heat stress in young rats. Acta Neurochir Suppl (Wien) 51:383–386

    CAS  Google Scholar 

  41. Elliott KA, Jasper H (1949) Measurement of experimentally induced brain swelling and shrinkage. Am J Phys 157(1):122–129

    CAS  Google Scholar 

  42. Sharma HS, Olsson Y, Persson S, Nyberg F (1995) Trauma-induced opening of the blood-spinal cord barrier is reduced by indomethacin, an inhibitor of prostaglandin biosynthesis. Experimental observations in the rat using [131I]-sodium, Evans blue and lanthanum as tracers. Restor Neurol Neurosci 7(4):207–215. doi:10.3233/RNN-1994-7403

    PubMed  Google Scholar 

  43. Sharma HS, Miclescu A, Wiklund L (2011) Cardiac arrest-induced regional blood-brain barrier breakdown, edema formation and brain pathology: a light and electron microscopic study on a new model for neurodegeneration and neuroprotection in porcine brain. J Neural Transm (Vienna) 118(1):87–114. doi:10.1007/s00702-010-0486-4

    Article  Google Scholar 

  44. Sharma HS, Kiyatkin EA (2009) Rapid morphological brain abnormalities during acute methamphetamine intoxication in the rat: An experimental study using light and electron microscopy. J Chem Neuroanat 37(1):18–32. doi:10.1016/j.jchemneu.2008.08.002

    CAS  Article  PubMed  Google Scholar 

  45. Kiyatkin EA, Sharma HS (2009) Permeability of the blood-brain barrier depends on brain temperature. Neuroscience 161(3):926–939. doi:10.1016/j.neuroscience.2009.04.004

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  46. Sharma HS, Olsson Y, Cervós-Navarro J (1993) Early perifocal cell changes and edema in traumatic injury of the spinal cord are reduced by indomethacin, an inhibitor of prostaglandin synthesis. Experimental study in the rat. Acta Neuropathol 85(2):145–153

    CAS  Article  PubMed  Google Scholar 

  47. Sharma HS, Zimmer C, Westman J, Cervós-Navarro J (1992) Acute systemic heat stress increases glial fibrillary acidic protein immunoreactivity in brain: experimental observations in conscious normotensive young rats. Neuroscience 48(4):889–901

    CAS  Article  PubMed  Google Scholar 

  48. Finder VH, Vodopivec I, Nitsch RM, Glockshuber R (2010) The recombinant amyloid-beta peptide Abeta1-42 aggregates faster and is more neurotoxic than synthetic Abeta1-42. J Mol Biol 396(1):9–18. doi:10.1016/j.jmb.2009.12.016

    CAS  Article  PubMed  Google Scholar 

  49. Van Dam D, De Deyn PP (2011) Animal models in the drug discovery pipeline for Alzheimer’s disease. Br J Pharmacol 164(4):1285–1300. doi:10.1111/j.1476-5381.2011.01299.x

    Article  PubMed  PubMed Central  Google Scholar 

  50. Laurijssens B, Aujard F, Rahman A (2013) Animal models of Alzheimer’s disease and drug development. Drug Discov Today Technol 10(3):e319–e327. doi:10.1016/j.ddtec.2012.04.001

    Article  PubMed  Google Scholar 

  51. Yamada K, Nabeshima T (2000) Animal models of Alzheimer’s disease and evaluation of anti-dementia drugs. Pharmacol Ther 88(2):93–113

    CAS  Article  PubMed  Google Scholar 

  52. Dorr A, Sahota B, Chinta LV, Brown ME, Lai AY, Ma K, Hawkes CA, McLaurin J et al (2012) Amyloid-β-dependent compromise of microvascular structure and function in a model of Alzheimer’s disease. Brain 135(Pt 10):3039–3050. doi:10.1093/brain/aws243

  53. Ni R, Gillberg PG, Bergfors A, Marutle A, Nordberg A (2013) Amyloid tracers detect multiple binding sites in Alzheimer’s disease brain tissue. Brain 136(Pt 7):2217–2227. doi:10.1093/brain/awt142

    Article  PubMed  Google Scholar 

  54. Blennow K, Mattsson N, Schöll M, Hansson O, Zetterberg H (2015) Amyloid biomarkers in Alzheimer’s disease. Trends Pharmacol Sci 36(5):297–309. doi:10.1016/j.tips.2015.03.002

    CAS  Article  PubMed  Google Scholar 

  55. Izco M, Martínez P, Corrales A, Fandos N, García S, Insua D, Montañes M, Pérez-Grijalba V et al (2014) Changes in the brain and plasma Aβ peptide levels with age and its relationship with cognitive impairment in the APPswe/PS1dE9 mouse model of Alzheimer’s disease. Neuroscience 263:269–279. doi:10.1016/j.neuroscience.2014.01.003

  56. Blennow K, Hampel H, Zetterberg H (2014) Biomarkers in amyloid-β immunotherapy trials in Alzheimer’s disease. Neuropsychopharmacology 39(1):189–201. doi:10.1038/npp.2013.154

    CAS  Article  PubMed  Google Scholar 

  57. Marr RA, Hafez DM (2014) Amyloid-beta and Alzheimer’s disease: the role of neprilysin-2 in amyloid-beta clearance. Front Aging Neurosci 6:187. doi:10.3389/fnagi.2014.00187

    PubMed  PubMed Central  Google Scholar 

  58. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer’s disease. Science 330(6012):1774. doi:10.1126/science.1197623

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  59. Lucey BP, Mawuenyega KG, Patterson BW, Elbert DL, Ovod V, Kasten T, Morris JC, Bateman RJ (2016) Associations between β-amyloid kinetics and the β-amyloid diurnal pattern in the central nervous system. JAMA Neurol. doi:10.1001/jamaneurol.2016.4202

  60. Roberts KF, Elbert DL, Kasten TP, Patterson BW, Sigurdson WC, Connors RE, Ovod V, Munsell LY et al (2014) Amyloid-β efflux from the central nervous system into the plasma. Ann Neurol 76(6):837–844. doi:10.1002/ana.24270

  61. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM (2006) Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med 12(7):856–861

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  62. Jha NK, Jha SK, Kumar D, Kejriwal N, Sharma R, Ambasta RK, Kumar P (2015) Impact of insulin degrading enzyme and neprilysin in Alzheimer’s disease biology: characterization of putative cognates for therapeutic applications. J Alzheimers Dis 48(4):891–917. doi:10.3233/JAD-150379

    CAS  Article  PubMed  Google Scholar 

  63. Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ et al (2009) Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice. J Neurosci 29(7):1977–1986. doi:10.1523/JNEUROSCI.2984-08.2009

  64. Li Y, Wang J, Zhang S, Liu Z (2015) Neprilysin gene transfer: a promising therapeutic approach for Alzheimer’s disease. J Neurosci Res 93(9):1325–1329. doi:10.1002/jnr.23564

    CAS  Article  PubMed  Google Scholar 

  65. Park MH, Lee JK, Choi S, Ahn J, Jin HK, Park JS, Bae JS (2013) Recombinant soluble neprilysin reduces amyloid-beta accumulation and improves memory impairment in Alzheimer’s disease mice. Brain Res 1529:113–124. doi:10.1016/j.brainres.2013.05.045

    CAS  Article  PubMed  Google Scholar 

  66. Liang K, Yang L, Yin C, Xiao Z, Zhang J, Liu Y, Huang J (2010) Estrogen stimulates degradation of beta-amyloid peptide by up-regulating neprilysin. J Biol Chem 285(2):935–942. doi:10.1074/jbc.M109.051664

    CAS  Article  PubMed  Google Scholar 

  67. Yang L, Hao J, Zhang J, Xia W, Dong X, Hu X, Kong F, Cui X (2009) Ginsenoside Rg3 promotes beta-amyloid peptide degradation by enhancing gene expression of neprilysin. J Pharm Pharmacol 61(3):375–380. doi:10.1211/jpp/61.03.0013

    CAS  Article  PubMed  Google Scholar 

  68. Ubhi K, Rockenstein E, Vazquez-Roque R, Mante M, Inglis C, Patrick C, Adame A, Fahnestock M et al (2013) Cerebrolysin modulates pronerve growth factor/nerve growth factor ratio and ameliorates the cholinergic deficit in a transgenic model of Alzheimer’s disease. J Neurosci Res 91(2):167–177. doi:10.1002/jnr.23142

  69. Yao XQ, Jiao SS, Saadipour K, Zeng F, Wang QH, Zhu C, Shen LL, Zeng GH et al (2015) p75NTR ectodomain is a physiological neuroprotective molecule against amyloid-beta toxicity in the brain of Alzheimer’s disease. Mol Psychiatry 20(11):1301–1310. doi:10.1038/mp.2015.49

  70. Cattaneo A, Calissano P (2012) Nerve growth factor and Alzheimer’s disease: new facts for an old hypothesis. Mol Neurobiol 46(3):588–604. doi:10.1007/s12035-012-8310-9

    CAS  Article  PubMed  Google Scholar 

  71. Paradisi M, Alviano F, Pirondi S, Lanzoni G, Fernandez M, Lizzo G, Giardino L, Giuliani A et al (2014) Human mesenchymal stem cells produce bioactive neurotrophic factors: source, individual variability and differentiation issues. Int J Immunopathol Pharmacol 27(3):391–402

  72. Lee JH, Lee JY, Yang SH, Lee EJ, Kim HW (2014) Carbon nanotube-collagen three-dimensional culture of mesenchymal stem cells promotes expression of neural phenotypes and secretion of neurotrophic factors. Acta Biomater 10(10):4425–4436. doi:10.1016/j.actbio.2014.06.023

    CAS  Article  PubMed  Google Scholar 

  73. Hofer HR, Tuan RS (2016) Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies. Stem Cell Res Ther 7(1):131. doi:10.1186/s13287-016-0394-0

    Article  PubMed  PubMed Central  Google Scholar 

  74. Caplan AI, Dennis J (2006) Mesenchymal stem cells as trophic mediators. J Cell Biochem 98(5):1076–1084

    CAS  Article  PubMed  Google Scholar 

  75. Zhang C, Zheng X, Wan X, Shao X, Liu Q, Zhang Z, Zhang Q (2014) The potential use of H102 peptide-loaded dual-functional nanoparticles in the treatment of Alzheimer’s disease. J Control Release 192:317–324. doi:10.1016/j.jconrel.2014.07.050

    CAS  Article  PubMed  Google Scholar 

  76. Kwon HJ, Cha MY, Kim D, Kim DK, Soh M, Shin K, Hyeon T, Mook-Jung I (2016) Mitochondria-targeting ceria nanoparticles as antioxidants for Alzheimer’s disease. ACS Nano 10(2):2860–2870. doi:10.1021/acsnano.5b08045

    CAS  Article  PubMed  Google Scholar 

  77. Liu Y, An S, Li J, Kuang Y, He X, Guo Y, Ma H, Zhang Y et al (2016) Brain-targeted co-delivery of therapeutic gene and peptide by multifunctional nanoparticles in Alzheimer’s disease mice. Biomaterials 80:33–45. doi:10.1016/j.biomaterials.2015.11.060

Download references

Acknowledgements

The study was supported by grants from the Air Force Office of Scientific Research (EOARD, London, UK), and Air Force Material Command, USAF, under grant number FA8655-05-1-3065; the Alzheimer’s Association (IIRG-09-132087), the National Institutes of Health (R01 AG028679) and the Dr. Robert M. Kohrman Memorial Fund (MAS, RJC); Swedish Medical Research Council (Nr 2710-HSS), Göran Gustafsson Foundation, Stockholm, Sweden (HSS); Astra Zeneca, Mölndal, Sweden (HSS/AS); The University Grants Commission, New Delhi, India (HSS/AS), Ministry of Science & Technology, Govt. of India (HSS/AS), Indian Medical Research Council, New Delhi, India (HSS/AS), and India-EU Co-operation Program (RP/AS/HSS) and IT 794/13 (JVL); Government of Basque Country and UFI 11/32 (JVL) University of Basque Country, Spain; and Society for Neuroprotection and Neuroplasticity (SSNN), Romania. Technical and human support provided by Dr. Ricardo Andrade from SGIker (UPV/EHU) is gratefully acknowledged. We thank Suraj Sharma, Uppsala, Sweden, for computer and graphic support. The US Government is authorized to reproduce and distribute reprints for government purpose notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the Air Force Office of Scientific Research or the US Government.

Author information

Authors and Affiliations

  1. Department of Surgical Sciences, Anesthesiology & Intensive Care Medicine, Uppsala University Hospital, Uppsala University, SE-75185, Uppsala, Sweden

    Hari Shanker Sharma & Aruna Sharma

  2. International Experimental Central Nervous System Injury & Repair (IECNSIR), University Hospital, Uppsala University, Frödingsgatan 12, Bldg. 28, SE-75421, Uppsala, Sweden

    Hari Shanker Sharma & Aruna Sharma

  3. Department of Clinical Neurosciences, University of Medicine & Pharmacy, Cluj-Napoca, Romania

    Hari Shanker Sharma & Dafin Fior Muresanu

  4. ”RoNeuro” Institute for Neurological Research and Diagnostic, 37 Mircea Eliade Street, 400364, Cluj-Napoca, Romania

    Dafin Fior Muresanu, Herbert Mössler & Aruna Sharma

  5. Department of Neurosciences, University of Basque Country, Bilbao, Spain

    Hari Shanker Sharma, José Vicente Lafuente & Aruna Sharma

  6. Nanoneurosurgery Group, BioCruces Health Research Institute, 48903, Barakaldo, Bizkaia, Spain

    José Vicente Lafuente

  7. Faculty of Health Science, Universidad Autónoma de Chile, Santiago de Chile, Chile

    José Vicente Lafuente

  8. School of Biomedical Engineering, Department of Biomaterials, Indian Institute of technology, Banaras Hindu University, Varanasi, India

    Ranjana Patnaik

  9. Department of Chemistry & Biochemistry, University of Arkansas, Fayetteville, AR, USA

    Z. Ryan Tian

  10. Department of Biomedical Engineering, University of Arkansas, Fayetteville, AR, USA

    Asya Ozkizilcik

  11. Department of Pathology, University of Maryland, Baltimore, MD, USA

    Rudy J. Castellani

Authors
  1. Hari Shanker Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dafin Fior Muresanu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. José Vicente Lafuente
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ranjana Patnaik
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Z. Ryan Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Asya Ozkizilcik
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rudy J. Castellani
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Herbert Mössler
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Aruna Sharma
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hari Shanker Sharma.

Ethics declarations

All experiments were carried out according to the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals and approved by the Local Institutional Ethics Committee.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sharma, H.S., Muresanu, D.F., Lafuente, J.V. et al. Co-Administration of TiO2 Nanowired Mesenchymal Stem Cells with Cerebrolysin Potentiates Neprilysin Level and Reduces Brain Pathology in Alzheimer’s Disease. Mol Neurobiol 55, 300–311 (2018). https://doi.org/10.1007/s12035-017-0742-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12035-017-0742-9

Keywords

  • Alzheimer’s disease (AD)
  • Neprilysin (NPL)
  • Amyloid-beta peptide (aβP)
  • Mesenchymal stem cells (MSCs)
  • Cerebrolysin (CBL)
  • TiO2 nanowires
  • Nanodelivery